Form 4: ADMA Biologics Director Exercises Options and Reports Beneficial Ownership Changes

Director Steve Elms of ADMA Biologics exercised stock options and reported changes in his beneficial ownership of company stock.

Summary

• Steve Elms, a director at ADMA Biologics, exercised 9,000 stock options at a price of $10.80 per share on November 27, 2024.
• This transaction increased his indirect holdings to 2,124,671 shares through Aisling Capital II LP.
• Mr. Elms also directly owns 76,441 shares, including 12,020 restricted stock units that will vest on February 26, 2025.
• The exercised options were set to expire soon, and they had vested fully by January 30, 2017.
• Mr. Elms has a limited power of attorney in place, allowing Adam S. Grossman and Michael A. Goldstein to file SEC reports on his behalf.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a stock option exercise, which is neither positive nor negative in itself. It's a neutral event from an investment perspective.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the ownership changes of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The exercise of stock options by a director is a common occurrence and is not unusual for companies with equity-based compensation plans.
• The reporting of beneficial ownership through investment funds like Aisling Capital II LP is also a typical scenario in the financial industry.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in ownership by a director.
• The exercise of options does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

ADMA Biologics, Steve Elms, stock options, beneficial ownership, SEC Form 4, director, equity securities